Literature DB >> 10949190

Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors.

P Milkiewicz1, B Gunson, S Saksena, M Hathaway, S G Hubscher, E Elias.   

Abstract

BACKGROUND/AIM: It remains uncertain whether autoimmune hepatitis (AIH), as an original indication for orthotopic liver transplantation (OLTX), predisposes to the development of chronic rejection (CR) after surgery and published reports on heterogeneous groups of patients provided conflicting data. In this work we analyzed the incidence and risk factors for CR in a large cohort of adult patients transplanted for AIH in our unit.
RESULTS: A total of 1190 adult patients received OLTX in our center between 1982 and 1998. A total of 77 patients (6.5%) were transplanted for AIH and 12 (15.6%) patients from this group developed clinical and histological features of CR within a median time of 3.5 months after OLTX. Patients with AIH who developed CR were younger than other AIH patients at OLTX (32 vs. 44.2 ys; P=0.015) and more often had histological features of moderate or severe acute rejection (83 vs. 34%; P=0.002) on early post-OLTX biopsies. The incidence of CR in AIH patients was significantly higher than in subjects transplanted for other indications such as primary biliary cirrhosis (8.2%; P<0.05), primary sclerosing cholangitis (5.2%; P<0.05) or alcoholic cirrhosis (2.0%; P<0.001). Also, we observed a tendency to decreased incidence of CR with time in all transplanted subjects.
CONCLUSIONS: Apart from younger age at OLTX and higher incidence of severe acute rejection, patients with AIH who developed CR did not differ from other subjects transplanted for this indication. Unlike other studies, not stratified by diagnosis, recipient CMV negative status, young donor age, and HLA DR matching were not identified as risk factors for CR in AIH.

Entities:  

Mesh:

Year:  2000        PMID: 10949190     DOI: 10.1097/00007890-200008150-00014

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients.

Authors:  Eun Jeong Kwak; Shahid Husain; Asia Obman; Lisa Meinke; Janet Stout; Shimon Kusne; Marilyn M Wagener; Nina Singh
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 3.  Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo.

Authors:  Alexis Gumm; Antonio Perez-Atayde; Andrew Wehrman
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-10-10

Review 4.  Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management.

Authors:  Oscar Mitchell; Arif M Cosar; Mohammad U Malik; Ahmet Gurakar
Journal:  Hepatol Int       Date:  2015-11-24       Impact factor: 6.047

Review 5.  Recurrence of autoimmune liver diseases after liver transplantation: clinical aspects.

Authors:  Evangelos Cholongitas; Andrew K Burroughs
Journal:  Auto Immun Highlights       Date:  2012-10-30

6.  Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation.

Authors:  Ana Cristina Aoun Tannuri; Fabiana Lima; Evandro Sobroza de Mello; Ryan Yukimatsu Tanigawa; Uenis Tannuri
Journal:  Clinics (Sao Paulo)       Date:  2016-04       Impact factor: 2.365

7.  Pediatric Liver Transplantation Program at the Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo.

Authors:  Ana Cristina Aoun Tannuri; Uenis Tannuri
Journal:  Clinics (Sao Paulo)       Date:  2016-04       Impact factor: 2.365

Review 8.  Recent updates on the management of autoimmune hepatitis.

Authors:  Atsumasa Komori
Journal:  Clin Mol Hepatol       Date:  2020-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.